Page 138 - 2020年2月第31卷第3期

neous immunoglobulin use in inclusion body myositis：a tive economic analysis[J]. Ann Allergy Asthma Immunol，
review of 6 cases[J]. Case Rep Neurol，2015，7（3）：227- 2018，120（2）：195-199.
232. [55] WINDEGGER TM，NGHIEM S，NGUYEN KH，et al.
[47] CHERIN P，TADMOURI A，DE JAEGER C，et al. Assess- Cost-utility analysis comparing hospital-based intrave-
ment of renal function in patients with myositis and treat- nous immunoglobulin with home-based subcutaneous im-
ed with subcutaneous immunoglobulin：a series of 24 cases munoglobulin in patients with secondary immunodeficien-
[J]. Ther Adv Musculoskelet Dis，2018，10（10）：201-207. cy[J]. Vox Sang，2019，114（3）：237-246.
[48] AYTEKIN G，ÇÖLKESEN F，ARDENIZ Ö，et al. Success- [56] ABOLHASSANI H，SADAGHIANI MS，AGHAMO-
ful immunoglobulin replacement with subcutaneous im- HAMMADI A，et al. Home-based subcutaneous immuno-
munoglobulin therapy in a patient with primary intestinal globulin versus hospital-based intravenous immunoglobu-
lymphangiectasia[J]. Asim Allerji Immunoloji，2019，17 lin in treatment of primary antibody deficiencies：system-
（1）：57-60. atic review and meta analysis[J]. J Clin Immunol，2012，32
[49] VISENTIN A，MAURO FR，ROSATI S，et al. Protective （6）：1180-1192.
role immunoglobulin replacement therapy in chronic lym- [57] ALTOOK R，KALICINSKY C，MIGUEL M，et al. Deliv-
phocytic leukemia：focus on subcutaneous immunoglobu- ery of subcutaneous immunoglobulin by rapid“push”in-
lin formulations[J]. Blood，2018.DOI：10.1182/blood- fusion for primary immunodeficiency patients[J]. J Aller-
2018-99-114867. gy Clin Immuno，2019.DOI：10.1186/s13223-019-0322-9.
[50] SCHEUERLEIN P，PIETSCH L，CAMACHO-ORDONEZ [58] HERRSCHER RF，PRINCE TL，VAN ANGLEN LJ，et al.
N，et al. Is it safe to switch from intravenous immunoglob- Efficacy，tolerability and persistence of subcutaneous im-
ulin to subcutaneous immunoglobulin in patients with munoglobulin provided through immunology physician
common variable immunodeficiency and autoimmune practices for the treatment of primary immunodeficiencies
thrombocytopenia?[J]. Front Immunol，2018.DOI：10.3389/ [J]. J Allergy Clin Immun，2019.DOI：10.1016/j.jaci.2018.
fimmu.2018.01656. eCollection 2018. 12.349.
[51] GANS M，GAGNE S，HSU D，et al. Refractory pericardi- [59] ROJAVIN MA，HOFMANN J，PRAUS M. Tolerability of
tis treated with concurrent subcutaneous immunoglobulin higher than current infusion rate and volume of the 20％
and interleukin 1 inhibitor therapy[J]. Ann Allergy Asthma subcutaneous immunoglobulin IgPro20 in primary immu-
Immunol，2018.DOI：10.1016/j.anai.2018.09.315. nodeficiency：an open-label multicenter study（HiLo）[J].
[52] GARDULF A，HAMMARSTROM L，SMITH CI.Home J Allergy Clin Immun，2019.DOI：10.1016/j.jaci.2018.12.
treatment of hypogammaglobulinaemia with subcutaneous 346.
gammaglobulin by rapid infusion[J]. Lancet，1991，338 [60] GUO Y，TIAN X，WANG X，et al. Adverse effects of im-
（8760）：162-166. munoglobulin therapy[J]. Front Immunol，2018. DOI：10.
[53] PONSFORD M，CARNE E，KINGDON C，et al. Facilitat- 3389/fimmu.2018.01299.
ed subcutaneous immunoglobulin（fSCIg）therapy-practi- [61] WASSERMAN RL. Personalized therapy：immunoglobu-
cal considerations[J]. Clin Exp Immunol，2015，182（3）： lin replacement for antibody deficiency[J]. Immunol Aller-
302-313. gy Clin，2019，39（1）：95-111.
[54] FU LW，SONG C，ISARANUWATCHAI W，et al. Home- （收稿日期：2019-06-20 修回日期：2019-09-10）
based subcutaneous immunoglobulin therapy vs hospi- （编辑：唐晓莲）
tal-based intravenous immunoglobulin therapy：a prospec-

《中国药房》杂志——中国科技核心期刊，欢迎投稿、订阅

·384 · China Pharmacy 2020 Vol. 31 No. 3 中国药房 2020年第31卷第3期